Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Gains from Sales and Divestitures (2024)

Historic Gains from Sales and Divestitures for Stoke Therapeutics (STOK) over the last 1 years, with Q4 2024 value amounting to $748238.0.

  • Stoke Therapeutics' Gains from Sales and Divestitures changed N/A to $748238.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $748238.0, marking a year-over-year change of. This contributed to the annual value of $748238.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Stoke Therapeutics reported Gains from Sales and Divestitures of $748238.0 as of Q4 2024.
  • Stoke Therapeutics' 5-year Gains from Sales and Divestitures high stood at $748238.0 for Q4 2024, and its period low was $748238.0 during Q4 2024.